Program By Day

7:00 AM-8:00 AM Complimentary Continental Breakfast
7:00 AM-6:30 PM Exhibits Open
7:55 AM-9:30 AM Welcome and General Session 4: Multimodality Management of Biliary Malignancies

Shishir Maithel, MD, FACS - Chair
Emory University Winship Cancer Institute

Ryan Fields, MD, FACS - Chair
Washington University School of Medicine in St. Louis

Shishir Maithel, MD, FACS
Emory University Winship Cancer Institute
Welcome of the Day

Juan W. Valle, MD
The Christie Hospital NHS Foundation Trust
Current State of Adjuvant Therapy for Biliary Tract Malignancies

Robin Kate Kelley, MD
University of California San Francisco
Advances in Molecular Targeted Therapies in Cholangiocarcinoma

Charles Rosen, MD
Mayo Clinic
Liver Transplantation for Cholangiocarcinoma: Indications and Outcomes

Panel Question and Answer
9:30 AM-10:00 AM Break
10:00 AM-11:30 AM General Session 5: Emerging Options for Hepatocellular Carcinoma—A Global Perspective

Josep Llovet, MD, PhD - Chair
Icahn School of Medicine at Mount Sinai

Riccardo Lencioni, MD - Chair
University of Miami Sylvester Comprehensive Cancer Center

Massimo Colombo, MD
Humanitas Research Hospital
The Effect of New Antiviral Therapies for Hepatitis C on the Occurrence and Recurrence of Hepatocellular Carcinoma

Richard K. G. Do, MD, PhD
Memorial Sloan Kettering Cancer Center
Diagnosis and Assessment of Response in Hepatocellular Carcinoma: LI-RADS, RECIST, and mRECIST

Edward Kim, MD, FSIR
Icahn School of Medicine at Mount Sinai
Locoregional Therapy With Selective Internal Radiotherapy for Hepatocellular Carcinoma: Where Do We Stand?

Jinsil Seong, MD, PhD
Yonsei University College of Medicine
Stereotactic Body Radiotherapy: What Role Does Focal Radiotherapy Play for Hepatocellular Carcinoma?

Ann-Lii Cheng, MD, PhD
National Taiwan University Hospital
Systemic Therapy for Advanced Hepatocellular Carcinoma

Panel Question and Answer
11:30 AM-1:00 PM Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
With Complimentary Boxed Lunch
11:30 AM-1:00 PM Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
12:00 PM-12:45 PM

Poster Walks

Open to all attendees. Meet at the Poster Assistance Desk. 

 

Ryan Fields, MD, FACS

Washington University School of Medicine in St. Louis

 

Philip Agop Philip, MD, PhD, FRCP

Karmanos Caner Institute 

1:00 PM-2:00 PM

Rapid-Fire Abstract Session: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Jason C. Cheng, MD, MS, PhD  - Chair
National Taiwan University Hospital

Shishir Maithel, MD, FACS - Chair
Emory University Winship Cancer Institute

 

Abstract 208: A phase IB/II randomized study of mFOLFIRINOX (mFFOX) + pegylated recombinant human hyaluronidase (PEGPH20) versus mFFOX alone in patients with good performance status metastatic pancreatic adenocarcinoma (mPC): SWOG S1313 (NCT #01959139).

First author: Ramesh Ramanathan, MD

 

Question and Answer

 

Abstract 209: KEYNOTE-224: Pembrolizumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib.

First author: Andrew Zhu

 

Question and Answer

 

Abstract 210: Effect of transarterial chemoembolization plus external beam radiotherapy on survival of patients with hepatocellular carcinoma showing macroscopic vascular invasion compared with sorafenib: A randomized trial.

First author: Sang Min Yoon

 

Question and Answer

 

Abstract 211: Genomics-driven precision medicine for advanced pancreatic ductal carcinoma (PDAC): Early results from the COMPASS trial (NCT02750657).

First author: Kyaw Aung, MBBS, MRCP, PhD

 

Question and Answer

1:00 PM-2:00 PM Breakout Session: Hereditary Gastrointestinal Cancer Syndromes

Aimee Lucas, MD, MS
Icahn School of Medicine at Mount Sinai
Genetic Syndromes Associated With Increased Risk of Pancreaticobiliary and Gastroduodenal Cancers

Sonia Kupfer, MD
University of Chicago
Optimal Screening and Surveillance of Genetically High-Risk Individuals

Flavio G. Rocha, MD
Virginia Mason Hospital and Medical Center
Surgical Management of Cancers in Patients with a Genetic Predisposition

Panel Question and Answer
1:00 PM-2:00 PM Breakout Session: Minimally Invasive Diagnostic and Interventional Techniques for Pancreaticobiliary Malignancies

James Farrell, MD
Yale School of Medicine, Yale University
Technologic Advances in Endoscopic Visualization of Cancer

Christopher J. Dimaio, MD
Icahn School of Medicine at Mount Sinai
Therapeutic Endoscopic Approaches to Pancreaticobiliary Tumors

Shailesh V. Shrikhande, MD, MS, FRCS
Tata Memorial Hospital
Minimally Invasive Surgical Approaches: Current Evidence

Panel Question and Answer
2:00 PM-2:15 PM Break
2:15 PM-3:45 PM

Oral Abstract Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Ryan Fields, MD, FACS  - Chair
Washington University School of Medicine in St. Louis

Flavio G. Rocha, MD  - Chair
Virginia Mason Hospital and Medical Center

 

Abstract 204: Phase II LAPACT Trial of nab-paclitaxel (nab-P) plus gemcitabine (G) for patients with locally advanced pancreatic cancer (LAPC).

First author: Pascal Hammel

 

Abstract 205: Randomized phase III study of gemcitabine plus S-1 combination therapy versus gemcitabine plus cisplatin combination therapy in advanced biliary tract cancer: A Japan Clinical Oncology Group study (JCOG1113, FUGA-BT).

First author: Chigusa Morizane, MD, PhD

 

Brian M. Wolpin, MD

Dana-Farber Cancer Institute

Discussion

 

Abstract 206: Randomized, Open Label, Multicenter, Phase II Trial comparing Transarterial Chemoembolization (TACE) plus Sorafenib with TACE Alone in Patients with Hepatocellular Carcinoma (HCC): TACTICS Trial.

First author: Masatoshi Kudo, MD, PhD

 

Abstract 207: Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: results from the randomized phase 3 CELESTIAL trial.

First author: Ghassan Abou-Alfa, MD

 

Jordi Bruix, MD, PhD

University of Barcelona

Discussion 

 

Panel Question and Answer

3:45 PM-4:15 PM Break
4:15 PM-5:30 PM General Session 6: Advanced and Metastatic Neuroendocrine Tumors (ARS)

Philip Agop Philip, MD, PhD, FRCP - Chair
Karmanos Cancer Institute

Michelle Kang Kim, MD, PhD - Chair
Icahn School of Medicine at Mount Sinai

Case 1: Synchronous Metastatic Midgut Neuroendocrine Tumor

Case 2: Gastric Neuroendocrine Tumor

Case 3: Unresectable Pancreatic Neuroendocrine

Massimo Falconi, MD
Università Vita Salute - Ospedale San Raffaele
Surgeon Perspective

Marianne Pavel, MD
Friedrich-Alexander University Erlangen-Nürnberg
Endocrine/Oncology Perspective

Parag Parikh, MD
Washington University School of Medicine in St. Louis
Radiation Oncologist Perspective

Wolfgang Weber, MD
Technical University of Munich
Nuclear Medicine Perspective

Michael C. Soulen, MD
University of Pennsylvania
Interventional Radiologist Perspective
5:30 PM-6:30 PM Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
With Complimentary Wine and Cheese Reception
5:30 PM-6:30 PM Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract